

Christopher L Shaffer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11947190/publications.pdf>

Version: 2024-02-01

39
papers

1,919
citations

304743

22
h-index

330143

37
g-index

39
all docs

39
docs citations

39
times ranked

2289
citing authors

#	ARTICLE	IF	CITATIONS
1	A Comprehensive Listing of Bioactivation Pathways of Organic Functional Groups. <i>Current Drug Metabolism</i> , 2005, 6, 161-225.	1.2	592
2	Analytical strategies for identifying drug metabolites. <i>Mass Spectrometry Reviews</i> , 2007, 26, 340-369.	5.4	279
3	Partial Agonists of the $\alpha_4\beta_2$ Neuronal Nicotinic Acetylcholine Receptor Reduce Ethanol Consumption and Seeking in Rats. <i>Neuropsychopharmacology</i> , 2011, 36, 603-615.	5.4	101
4	Formation of Cyclopropanone during Cytochrome P450-Catalyzed N-Dealkylation of a Cyclopropylamine. <i>Journal of the American Chemical Society</i> , 2002, 124, 8268-8274.	13.7	81
5	N-Dealkylation of an N-Cyclopropylamine by Horseradish Peroxidase. Fate of the Cyclopropyl Group. <i>Journal of the American Chemical Society</i> , 2001, 123, 8502-8508.	13.7	67
6	A Rational Chemical Intervention Strategy To Circumvent Bioactivation Liabilities Associated with a Nonpeptidyl Thrombopoietin Receptor Agonist Containing a 2-Amino-4-arylthiazole Motif. <i>Chemical Research in Toxicology</i> , 2007, 20, 1954-1965.	3.3	52
7	Discovery and Preclinical Characterization of 1-Methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): A Highly Potent, Selective, and Efficacious Metabotropic Glutamate Receptor 5 (mGluR5) Negative Allosteric Modulator. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 861-877.	6.4	51
8	Strategies to optimize the brain availability of central nervous system drug candidates. <i>Expert Opinion on Drug Discovery</i> , 2011, 6, 371-381.	5.0	48
9	Glycine transporter inhibition reverses ketamine-induced working memory deficits. <i>NeuroReport</i> , 2010, 21, 390-394.	1.2	47
10	Prevention of ketamine-induced working memory impairments by AMPA potentiators in a nonhuman primate model of cognitive dysfunction. <i>Behavioural Brain Research</i> , 2010, 212, 41-48.	2.2	46
11	Positive Allosteric Modulation of AMPA Receptors from Efficacy to Toxicity: The Interspecies Exposure-Response Continuum of the Novel Potentiator PF-4778574. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 347, 212-224.	2.5	46
12	Enhancing ketamine translational pharmacology via receptor occupancy normalization. <i>Neuropharmacology</i> , 2014, 86, 174-180.	4.1	46
13	An Evaluation of Using Rat-Derived Single-Dose Neuropharmacokinetic Parameters to Project Accurately Large Animal Unbound Brain Drug Concentrations. <i>Drug Metabolism and Disposition</i> , 2012, 40, 2162-2173.	3.3	40
14	Defining Neuropharmacokinetic Parameters in CNS Drug Discovery to Determine Cross-Species Pharmacologic Exposure-Response Relationships. <i>Annual Reports in Medicinal Chemistry</i> , 2010, 45, 55-70.	0.9	37
15	Enzymatic N-Dealkylation of an N-Cyclopropylamine: An Unusual Fate for the Cyclopropyl Group. <i>Journal of the American Chemical Society</i> , 2001, 123, 349-350.	13.7	34
16	BIOTRANSFORMATION OF A GABAA RECEPTOR PARTIAL AGONIST IN SPRAGUE-DAWLEY RATS AND CYNOMOLGUS MONKEYS: IDENTIFICATION OF TWO UNIQUE N-CARBAMOYL METABOLITES. <i>Drug Metabolism and Disposition</i> , 2005, 33, 1688-1699.	3.3	31
17	Prediction of Human Brain Penetration of P-glycoprotein and Breast Cancer Resistance Protein Substrates Using In Vitro Transporter Studies and Animal Models. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 2225-2235.	3.3	30
18	Using a Tritiated Compound to Elucidate Its Preclinical Metabolic and Excretory Pathways in Vivo: Exploring Tritium Exchange Risk. <i>Drug Metabolism and Disposition</i> , 2006, 34, 1615-1623.	3.3	28

#	ARTICLE	IF	CITATIONS
19	Mechanisms of Skin Toxicity Associated with Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators. <i>Cell Chemical Biology</i> , 2017, 24, 858-869.e5.	5.2	26
20	Metabolism and Disposition of a Selective $\alpha 7$ Nicotinic Acetylcholine Receptor Agonist in Humans. <i>Drug Metabolism and Disposition</i> , 2007, 35, 1188-1195.	3.3	25
21	Discovery and Characterization of a Novel Dihydroisoxazole Class of α -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) Receptor Potentiators. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 9180-9191.	6.4	24
22	Pharmacological evaluation of clinically relevant concentrations of (2R,6R)-hydroxynorketamine. <i>Neuropharmacology</i> , 2019, 153, 73-81.	4.1	24
23	The Discovery and Characterization of the α -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Potentiator α -[3-(4-(4-(5-Cyano-2-thienyl)phenoxy)tetrahydrofuran-3-yl)propane-2-sulfonamide (PF-04958242)]. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 4291-4308.	6.4	23
24	Phosphodiesterase 10A inhibitor MP-10 effects in primates: Comparison with risperidone and mechanistic implications. <i>Neuropharmacology</i> , 2014, 77, 257-267.	4.1	22
25	Metabolism of a $^{14}C/3H$ -labeled GABAA receptor partial agonist in rat, dog and human liver microsomes: Evaluation of a dual-radiolabel strategy. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2007, 43, 1195-1205.	2.8	17
26	Using Simcyp to project human oral pharmacokinetic variability in early drug research to mitigate mechanism-based adverse events. <i>Biopharmaceutics and Drug Disposition</i> , 2012, 33, 72-84.	1.9	17
27	Therapeutic doses of antidepressants are projected not to inhibit human $\alpha 4\beta 2$ nicotinic acetylcholine receptors. <i>Neuropharmacology</i> , 2013, 72, 88-95.	4.1	15
28	Diphenhydramine has Similar Interspecies Net Active Influx at the Blood-Brain Barrier. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 1557-1562.	3.3	12
29	Drug-induced Skin Lesions in Cynomolgus Macaques Treated with Metabotropic Glutamate Receptor 5 (mGluR5) Negative Allosteric Modulators. <i>Toxicologic Pathology</i> , 2015, 43, 995-1003.	1.8	10
30	Biotransformation of an $\alpha 4\beta 2$ Nicotinic Acetylcholine Receptor Partial Agonist in Sprague-Dawley Rats and the Dispositional Characterization of Its N-Carbamoyl Glucuronide Metabolite. <i>Drug Metabolism and Disposition</i> , 2009, 37, 1480-1489.	3.3	8
31	Species Differences in the Biotransformation of an $\alpha 4\beta 2$ Nicotinic Acetylcholine Receptor Partial Agonist: The Effects of Distinct Glucuronide Metabolites on Overall Compound Disposition. <i>Drug Metabolism and Disposition</i> , 2010, 38, 292-301.	3.3	7
32	Assessment of adverse effects of neurotropic drugs in monkeys with the Drug Effects on the Nervous System (DENS) scale. <i>Journal of Neuroscience Methods</i> , 2013, 215, 97-102.	2.5	7
33	Discovery and Characterization of (R)-6-Neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-one (PF-06462894), an Alkyne-Lacking Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator Profiled in both Rat and Nonhuman Primates. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7764-7780.	6.4	7
34	Reverse and Forward Translational Neuropharmacology in Psychiatric Drug Discovery. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 193-195.	4.7	6
35	Quantitative projection of human brain penetration of the $H 3$ antagonist PF-03654746 by integrating rat-derived brain partitioning and PET receptor occupancy. <i>Xenobiotica</i> , 2017, 47, 119-126.	1.1	5
36	Antimicrobial prescribing for treatment of serious infections caused by Staphylococcus aureus and methicillin-resistant Staphylococcus aureus in pediatrics: an expert review. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1107-1116.	4.4	5

#	ARTICLE	IF	CITATIONS
37	Metabolism and Disposition of a $\hat{1}^3$ -Aminobutyric Acid Type A Receptor Partial Agonist in Humans. Drug Metabolism and Disposition, 2008, 36, 655-662.	3.3	3
38	The effect of ketamine-contaminated control plasma on small-molecule plasma protein binding. Bioanalysis, 2013, 5, 2607-2612.	1.5	0
39	An investigation of metabotropic glutamate receptor 5 negative allosteric modulators in physiological and behavioral indicators of anxiety and cognition in rodents. FASEB Journal, 2013, 27, 1099.4.	0.5	0